12/11/2020 9:01:26 AM
Arena Pharmaceuticals To Present Data From The Phase 2b ADVISE Trial - Late-Breaker
12/8/2020 8:39:53 AM
Arena Pharma Says Achieves Target Enrollment For Etrasimod Phase 3 ELEVATE UC 52 Trial
11/9/2020 4:09:16 PM
Arena Pharmaceuticals Q3 Loss/share $1.69 Vs. Loss $.46 Year Ago
11/9/2020 4:04:46 PM
Arena Says Etrasimod Did Not Meet Ph 2b Primary Endpoint Of EASI Change From Baseline At Week 12
10/28/2020 8:33:50 AM
Arena Pharma Announces Launch Of Longboard Pharmaceuticals With $56 Mln Financing
10/20/2020 4:03:49 PM
Arena Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/1/2020 8:31:56 AM
Arena Completes Full Enrollment Of Phase 2b CAPTIVATE Trial Evaluating Olorinab
9/16/2020 8:32:36 AM
Arena Pharma Announces First Subject Dosed In ELEVATE UC 12 Global Phase 3 Trial Of Etrasimod In Ulcerative Colitis
9/1/2020 8:31:50 AM
Arena Says First Subject Dosed In Phase 2 Trial Evaluating Etrasimod In Alopecia Areata
8/5/2020 4:04:25 PM
Arena Q2 Loss/Shr $$1.61 Vs Loss $1.24 Last Year